Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Explore linked clinical trials.8 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic Neuralgia | Neuralgia, Postherpetic, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, neuralgia, neuromuscular disease, peripheral nervous system disorder | Recruiting | Phase 2 | 2026-08-11 | NCT07758920 | |
| Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS | Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Sepsis, Systemic Inflammatory Response Syndrome, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-02-17 | NCT07413094 | |
| Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery | Moderate to Severe Acute Postoperative Pain | Recruiting | Phase 2 | 2025-12-30 | NCT07311369 | |
| Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery | Moderate to Severe Acute Postoperative Pain | Recruiting | Phase 2 | 2025-12-22 | NCT07147049 | |
| A Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps | Chronic Sinusitis Without Nasal Polyps | Recruiting | Phase 2 | 2025-09-19 | NCT07174115 | |
| Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathic Pain | Not yet recruiting | Phase 2 | 2025-09-08 | NCT07159243 | |
| Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants | Healthy Participants | Recruiting | Phase 1 | 2025-08-24 | NCT06912295 | |
| Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of YD0293 in Healthy Subjects | Healthy Participants | Enrolling by invitation | Phase 1 | 2025-08-17 | NCT07098091 |